RxDoctor Payments Data

Gregory Stevens, MD

Internal Medicine · Auburn Hills, MINPI 1275672420

Payments from drug & device makers

$11,797in general payments, 2019–2025

Across 507 payments — averaging $23.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Amgen$1K
  • Boehringer Ingelheim$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • AbbVie$839
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$11,37496%
  • Education$4234%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,797 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$90,221
Medicare patients
258
Services billed
933

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$39,015
EliquisApixaban43$32,622
MounjaroTirzepatide24$29,753
JardianceEmpagliflozin24$22,622
XareltoRivaroxaban15$20,601
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$17,593
EntrestoSacubitril/Valsartan17$14,360
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$9,356
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$3,647
DayvigoLemborexant11$3,549
Levothyroxine Sodium161$2,460
Tamsulosin Hcl99$2,122
Metoprolol Succinate80$1,560
Atorvastatin Calcium137$1,446
SynthroidLevothyroxine Sodium13$1,201

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,231$39,01537 claims
PfizerEliquis$308$32,62243 claims
Lilly USA, LLCMounjaro$1,273$29,75324 claims
Boehringer IngelheimJardiance$1,425$22,62224 claims
GSKTrelegy Ellipta$215$17,59316 claims
NovartisEntresto$80$14,36017 claims
AbbVieSynthroid$839$1,20113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Auburn Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →